Cancer Letters
Volume 230, Issue 1 , Pages 72-80 , 8 December 2005

Regulation of human peptide transporter 1 (PEPT1) in gastric cancer cells by anticancer drugs

Received 25 October 2004 ,Revised 15 December 2004 ,Accepted 18 December 2004.

References 

  1. Terada T, Inui K. Peptide transporters: structure, function, regulation and application for drug delivery. Curr. Drug Metab. 2004;5:85–94
  2. Gonzalez DE, Covitz KM, Sadee W, Mrsny RJ. An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res. 1998;58:519–525
  3. Knutter I, Rubio-Aliaga I, Boll M, Hause G, Daniel H, Neubert K, et al. H+-peptide cotransport in the human bile duct epithelium cell line SK-ChA-1. Am. J. Physiol. Gastrointest. Liver Physiol. 2002;283:G222–G229
  4. Nakanishi T, Tamai I, Takaki A, Tsuji A. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int. J. Cancer. 2000;88:274–280
  5. Neumann J, Brandsch M. δ-aminolevulinic acid transport in cancer cells of the human extrahepatic biliary duct. J. Pharmacol. Exp. Ther. 2003;305:219–224
  6. Adibi SA. Regulation of expression of the intestinal oligopeptide transporter (Pept-1) in health and disease. Am. J. Physiol. Gastrointest. Liver Physiol. 2003;285:G779–G788
  7. Tanaka H, Miyamoto KI, Morita K, Haga H, Segawa H, Shiraga T, et al. Regulation of the PepT1 peptide transporter in the rat small intestine in response to 5-fluorouracil-induced injury. Gastroenterology. 1998;114:714–723
  8. Satoh J, Tsujikawa T, Fujiyama Y, Bamba T. Nutritional benefits of enteral alanyl-glutamine supplementation on rat small intestinal damage induced by cyclophosphamide. J. Gastroenterol. Hepatol. 2003;18:719–725
  9. Berlioz F, Maoret JJ, Paris H, Laburthe M, Farinotti R, Roze C. α2-adrenergic receptors stimulate oligopeptide transport in a human intestinal cell line. J. Pharmacol. Exp. Ther. 2000;294:466–472
  10. Fujita T, Majikawa Y, Umehisa S, Okada N, Yamamoto A, Ganapathy V, et al. σ Receptor ligand-induced up-regulation of the H+/peptide transporter PEPT1 in the human intestinal cell line Caco-2. Biochem. Biophys. Res. Commun. 1999;261:242–246
  11. Becker KF, Keller G, Hoefler H. The use of molecular biology in diagnosis and prognosis of gastric cancer. Surg. Oncol. 2000;9:5–11
  12. Yasui W, Oue N, Ito R, Kuraoka K, Nakayama H. Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci. 2004;95:385–392
  13. Saito H, Okuda M, Terada T, Sasaki S, Inui K. Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of β-lactam antibiotics in the intestine and kidney. J. Pharmacol. Exp. Ther. 1995;275:1631–1637
  14. Terada T, Saito H, Mukai M, Inui K. Identification of the histidine residues involved in substrate recognition by a rat H+/peptide cotransporter, PEPT1. FEBS Lett. 1996;394:196–200
  15. Ashida K, Katsura T, Motohashi H, Saito H, Inui K. Thyroid hormone regulates the activity and expression of the peptide transporter PEPT1 in Caco-2 cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2002;282:G617–G623
  16. Terada T, Sawada K, Saito H, Hashimoto Y, Inui K. Functional characteristics of basolateral peptide transporter in the human intestinal cell line Caco-2. Am. J. Physiol. 1999;276:G1435–G1441
  17. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976;72:248–254
  18. Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int. J. Cancer. 2004;109:926–932
  19. Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003;97:1015–1024
  20. Noguchi Y, Saito A, Miyagi Y, Yamanaka S, Marat D, Doi C, et al. Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett. 2002;154:175–182
  21. Fuchs BC, Perez JC, Suetterlin JE, Chaudhry SB, Bode BP. Inducible antisense RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2004;286:G467–G478
  22. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer. 2003;3:330–338
  23. Osaki M, Tatebe S, Goto A, Hayashi H, Oshimura M, Ito H. 5-Fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: role of the p53 gene. Apoptosis. 1997;2:221–226
  24. Jung ID, Yang SY, Park CG, Lee KB, Kim JS, Lee SY, et al. 5-Fluorouracil inhibits nitric oxide production through the inactivation of IκB kinase in stomach cancer cells. Biochem. Pharmacol. 2002;64:1439–1445
  25. Pan X, Terada T, Okuda M, Inui K. Altered diurnal rhythm of intestinal peptide transporter by fasting and its effects on the pharmacokinetics of ceftibuten. J. Pharmacol. Exp. Ther. 2003;307:626–632
  26. Ogihara H, Suzuki T, Nagamachi Y, Inui K, Takata K. Peptide transporter in the rat small intestine: ultrastructural localization and the effect of starvation and administration of amino acids. Histochem. J. 1999;31:169–174
  27. Izuishi K, Kato K, Ogura T, Kinoshita T, Esumi H. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res. 2000;60:6201–6207

PII: S0304-3835(04)01001-8

doi: 10.1016/j.canlet.2004.12.023

Cancer Letters
Volume 230, Issue 1 , Pages 72-80 , 8 December 2005

Article Tools

* Image Usage & Resolution